All In Biotech

Drug Trial Radar · NCT07151040

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

A First-in-human, Phase 1/2, Multicenter, Open-label, Dose Escalation, Confirmation and Expansion Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of TH9619 in Subjects With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

43

Planned (sponsor's estimate)

Start

Aug 22, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
One-carbon Therapeutics ABIndustry
Sponsor type
Industry
First posted
Sep 2, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human, multi-center, open-label, dosage escalation study to determine the recommended dose range of TH9619 in subjects with advanced cancer.

Conditions

  • Solid Tumor
  • Colorectal Cancer (CRC)
  • Squamous Cell Carcinoma of Head and Neck
  • Non-Small Cell Lung Cancer (NSCLC)
  • Gastrooesophageal Junction Cancer
  • Gastric Cancer

Interventions

  • TH9619Drug

    Phase 1a - DOSE ESCALATION Description: Single arm dose escalation of TH9619 as monotherapy. Phase 1b - DOSE EXPANSION Description: Single arm dose expansion of TH9619 as monotherapy in selected tumor types. The objectives and endpoints for the expansion cohort(s) will be defined in a protocol amendment, once data from Phase 1a are available.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of treatment-emergent adverse events (TEAEs)Time frame: From the start of Cycle 1 Day 1, through the 28-day study treatment cycles and follow-up, up to 2 years.
  2. Incidence of severe treatment-emergent adverse events (TEAEs) per Common Terminology for Adverse Events (CTCAE) V5.0 gradingTime frame: From the start of Cycle 1 Day 1, through the 28-day study treatment cycles and follow-up, up to 2 years.
  3. Incidence of treatment-emergent adverse events (TEAEs) related to treatment, as assessed by the InvestigatorTime frame: From the start of Cycle 1 Day 1, through the 28-day study treatment cycles and follow-up, up to 2 years.
  4. Frequency of serious adverse events (SAEs)Time frame: From the screening visit (maximum 28 days from Cycle 1 Day 1), through the 28-day study treatment cycles and follow-up, up to 2 years.
  5. Incidence of serious adverse events (SAEs) per the seriousness criteria defined in the protocol.Time frame: From the screening visit (maximum 28 days from Cycle 1 Day 1), through the 28-day study treatment cycles and follow-up, up to 2 years.
  6. Incidence of serious adverse events (SAEs) related to treatment, as assessed by the InvestigatorTime frame: From the start of Cycle 1 Day 1, through the 28-day study treatment cycles and follow-up, up to 2 years.
  7. Incidence of out of range clinical laboratory tests (as defined by the clinic) assessed as clinically significant by the InvestigatorTime frame: From the screening visit (maximum 28 days from Cycle 1 Day 1), through the 28-day study treatment cycles and follow-up, up to 2 years.
  8. Incidence of findings on vital signs parameters assessed as clinically significant by the InvestigatorTime frame: From the screening visit (maximum 28 days from Cycle 1 Day 1), through the 28-day study treatment cycles and follow-up, up to 2 years.
  9. Incidence of findings on ECHO/ECG assessed as clinically significant by the InvestigatorTime frame: From the screening visit (maximum 28 days from Cycle 1 Day 1), through the 28-day study treatment cycles and follow-up, up to 2 years.
  10. Incidence of findings during physical examinations assessed as clinically significant by the InvestigatorTime frame: From the screening visit (maximum 28 days from Cycle 1 Day 1), through the 28-day study treatment cycles and follow-up, up to 2 years.
  11. Incidence of treatment emergent adverse events (TEAEs) leading to dose interruptions/reductions and/or discontinuation of treatmentTime frame: From the start of Cycle 1 Day 1, through the 28-day study treatment cycles and follow-up, up to 2 years.

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • Vall D Hebron Institute Of Oncology

    Barcelona, Spain · Recruiting

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • Newcastle University

    Newcastle upon Tyne, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.